跳至主要内容
临床试验/ISRCTN30128134
ISRCTN30128134已完成未知

Prospective clinical study of Indocyanine-Green dye immune cell imaging in the human eye

niversity of Bristol0 个研究点目标入组 12 人开始时间: 2017年4月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
12

研究概览

简要总结

2020 results in https://doi.org/10.1371/journal.pone.0226311 (added 24/02/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. 18 years of age or over with legal capacity to consent
  • 2. Able to travel and attend the full programme within the funded travel cost budget
  • In addition, ocular inclusion criteria must be met:
  • Cohort 1 - recruitment of 8 patients:
  • 1. With likely or suspected Choroidal Neovascular Membrane or Central Serous Retinopathy that clinically requires ICG angiography (with or without combined fluorescein angiography)
  • 2. Macular sub-retinal fluid is present and at least 500µm in diameter on a spectral-domain OCT scan
  • 3. Any obscuring haemorrhage should not exceed more than 50% of the area of the sub-retinal fluid
  • 4. Not due for intravitreal injection or photodynamic therapy within the first 48 hours of the study period
  • Cohort 2 - recruitment of 4 patients:
  • 1. With likely or suspected posterior uveitis or panuveitis that clinically requires ICG angiography (with or without combined fluorescein angiography)
  • 2. Clinically suspected vasculitis
  • 3. No intravitreal therapy has been administered within 3 months prior or will be administered during the study period
  • 4. Mild vitritis only (with a SUN Haze score =2)
  • Cohort 3 - recruitment of 3 healthy control volunteers:
  • 1. No known ocular pathology
  • 2. No known refractive error larger than +3.00 dioptres or -3.00 dioptres spherical equivalent in either eye
  • 3. Self reported normal community optometry examination within one year prior to recruitment
  • 4. Normal colour fundal photography at start of study
  • Cohort 4 - recruitment of 3 patients:
  • 1. Known ocular pathology where ICG angiography is not normally indicated
  • 2. Diagnoses can include Diabetic Macular Oedema, Proliferative Diabetic Retinopathy, cystoid macular oedema, geographic atrophy or other forms of uveitis not included in Cohort 2
  • 3. Patients meeting the criteria for Cohorts 1 and 2 may also be included, but given ICG alone without combined Fluorescein as in the usual standard of care

排除标准

  • 1. Known fluorescein, ICG, iodine or shellfish allergy
  • 2. Any known contraindication to topical Tropicamide and Phenylephrine dilating drops
  • 3. Known renal (eGFR =80 mL/min/1.73m2) or hepatic dysfunction or active disease that in the opinion of the investigator will contraindicate the administration of ICG
  • 4. Unable to be easily imaged on Spectralis, Optos or Topcon retinal imaging machines (e.g. marked kyphosis or physical impairment)
  • 5. Significant media opacity leading to poor image quality. (e.g. vitreous haemorrhage or cataract)
  • 6. Unable to donate a peripheral blood sample or known HIV, Hep B or C
  • 7. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation. A pregnancy test will be performed on all female participants of childbearing age prior to ICG injection
  • 8. Each participant may only enter the study once and cannot currently be enrolled in another research trial

研究者

发起方
niversity of Bristol

相似试验